BLT 0.00% 1.3¢ blis technologies limited ordinary shares

Ann: GENERAL: BLT: Preliminary Results for BLIS probiotic trial

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. lightbulb Created with Sketch. 2
    • Release Date: 26/11/15 11:20
    • Summary: GENERAL: BLT: Preliminary Results for BLIS probiotic trial
    • Price Sensitive: No
    • Download Document  664B
    					BLT
    26/11/2015 11:20
    GENERAL
    NOT PRICE SENSITIVE
    REL: 1120 HRS BLIS Technologies Limited
    
    GENERAL: BLT: Preliminary Results for BLIS probiotic trial
    
    Preliminary results from a field trial in the Eastern Bay of Plenty using
    BLIS K12 probiotic presented to the Paediatric Society of New Zealand
    yesterday indicated that a one month course of BLIS K12 probiotic achieves a
    useful, greater decrease in both Group A Streptococcal (GAS) carriage and GAS
    sore throats than antibiotics alone.  Further analysis of the results are
    being undertaken and presented early next year.
    
    Peter Fennessy
    Chairman
    End CA:00274150 For:BLT    Type:GENERAL    Time:2015-11-26 11:20:37
    				
 
watchlist Created with Sketch. Add BLT (NZSX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.